ArticleJournal of diabetes and metabolic disorders2022
Article in Journal of diabetes and metabolic disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 4 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Materials: Based upon the literature survey various compounds of the asafoetida was deduced from the Pubchem and protein structure was deduced from protein data bank. Virtual screening was performed using Pyrx with α- amylase and α- glucosidase. Compounds with highest binding affinity score and 3-d interaction analysis was used to identify the potential inhibitors among various compounds. Pharmacokinetic studies for Drug likeliness and toxicity properties were characterized using SWISS ADME and ADMETSAR webservers. Results: The docking scores, bindging affinity and 3d structure studies showed that Kamolonol, Gummosin, Picealactone B, Farnesiferol A are showing potential anti α- amylase whereas Epi-conferdione, Conferol, Feselol, and Farnesiferol C shows α- glucosidase inhibitory properties. The qualitative structural activity relationship for drug-likeness, pharmacokinetics and carcinogenicity analysis indicates that they are safe as drug molecules as these compounds follows the various parameters such as Lipinski's rule of 5, anti-carcinogenicity etc. Conclusions: This study shows that phytochemicals of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.